As­traZeneca ax­es li­cense agree­ment with Aridis, plac­ing Eu­rope-fund­ed PhI­II on hold

As­traZeneca is scrap­ping its li­cense agree­ment with Aridis Phar­ma­ceu­ti­cals on March 30, the British Big Phar­ma told the biotech last week, send­ing a Eu­ro­pean-fund­ed Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER